FDA Approves New Hepatitis B Injection That Could Help Some Patients Stop Long-Term Medication
The U.S. Food and Drug Administration (FDA) has approved a new treatment for certain adults living with chronic hepatitis B, offering hope for patients who want to control the infection without taking antiviral medication indefinitely.
The newly approved drug, called Hibsago (bepirovirsen), represents a different approach to managing hepatitis B. Unlike traditional antiviral medicines that primarily suppress the virus, this treatment targets the genetic messages the virus uses to reproduce. For eligible patients, the treatment may help the immune system maintain control of the infection after medication is discontinued.
The approval, announced on October 20, 2026, marks a significant development in the treatment of chronic hepatitis B. However, the drug is not suitable for everyone, and patients must meet specific medical criteria before considering it.
What Is Hibsago and How Does It Work?
Hibsago is a new hepatitis B treatment developed by pharmaceutical company GSK. Its active ingredient, bepirovirsen, works differently from existing antiviral medications.
Chronic hepatitis B is a long-term viral infection that affects the liver. Current treatments generally focus on suppressing viral activity, helping protect the liver from ongoing damage. Although these medicines can be highly effective, many patients need to take them for years.
Hibsago targets the genetic instructions that hepatitis B uses to produce viral components. By interfering with these messages, the medication aims to reduce viral activity and levels of hepatitis B surface antigen, a protein associated with the infection.
The goal is to help the body's immune system gain better control over the virus.
For some patients, this could mean maintaining control of hepatitis B without continued medication. However, treatment success varies, and the possibility of stopping medication depends on follow-up assessments and laboratory results.
Why Is This Approval Important?
Chronic hepatitis B remains a significant public health concern. According to GSK, approximately 1.7 million people in the United States are living with the infection.
Without appropriate monitoring and management, chronic hepatitis B can cause long-term liver damage. Potential complications include liver scarring, known as cirrhosis, and an increased risk of liver cancer.
Existing antiviral medicines can help reduce these risks by controlling viral replication. However, treatment often involves taking medication daily for extended periods.
For some patients, this creates practical and emotional challenges, including the burden of long-term medication use, ongoing medical appointments, and the need for continued monitoring.
Hibsago introduces another potential treatment option for a carefully selected group of adults. Its main significance is the possibility of achieving what specialists call a functional cure, in which the infection remains under control without continuous antiviral treatment.
Nevertheless, a functional cure is not the same as completely eliminating every trace of the virus from the body.
Who Can Receive Hibsago?
The FDA has approved Hibsago for specific adults with chronic hepatitis B who meet defined eligibility requirements.
According to the reported approval details, eligible patients must:
- Be adults without cirrhosis.
- Have received antiviral treatment for at least six months.
- Have hepatitis B that is already suppressed by their existing medication.
- Have low levels of hepatitis B surface antigen.
These restrictions are important because the treatment has not been approved for every person living with hepatitis B.
Patients with advanced liver disease or those who do not meet the required laboratory criteria may not qualify. A liver specialist or other qualified healthcare professional can determine whether the treatment is appropriate.
Patients should not stop their current antiviral medication or change their treatment plan without consulting their healthcare provider.
How Is the New Treatment Administered?
Hibsago is given as an injection under the skin over a treatment period of up to six months.
Patients initially receive the medication as part of a treatment plan that also includes their existing antiviral medicine. According to GSK, patients may be able to administer the injections themselves after the first dose, provided they receive the appropriate instructions.
After completing the injection course, patients continue to undergo medical assessments to determine whether the treatment has produced a sufficient response.
Some individuals who meet the required clinical and laboratory criteria may subsequently be able to stop their regular hepatitis B medication.
However, discontinuing treatment is not automatic. Decisions depend on the patient's response, test results, and the treating specialist's assessment.
Continued monitoring remains essential even when medication is stopped.
What Did Clinical Trials Reveal?
The FDA's approval was supported by findings from two clinical trials examining the effectiveness of bepirovirsen in people with chronic hepatitis B.
According to the reported results, approximately 24% of patients who received Hibsago met the criteria required to discontinue their existing hepatitis B treatment. None of the patients who received a placebo achieved the same outcome.
Researchers also reported that six months after stopping all hepatitis B treatment, 19% of patients who had received Hibsago continued to maintain viral control, with hepatitis B surface antigen no longer detectable in their blood.
These findings suggest that the treatment may help a subset of patients achieve sustained control of the infection without ongoing medication.
However, the results also highlight an important limitation: most patients did not achieve the reported treatment-free outcome.
The findings should therefore be interpreted carefully. Hibsago offers a promising additional option, but it does not guarantee that every patient will be able to stop antiviral medication.
Further clinical experience and continued research will help clarify how well the treatment performs across different patient groups and over longer periods.
What Are the Possible Risks and Side Effects?
Despite its potential benefits, Hibsago carries important safety warnings.
According to the reported FDA approval information, the drug's prescribing information includes a boxed warning, the agency's strongest type of safety warning, concerning severe liver reactions and low platelet counts.
Platelets are blood cells that help the body form clots and control bleeding. When platelet levels become dangerously low, patients may face an increased risk of serious or potentially life-threatening bleeding.
Severe liver reactions are another major concern, particularly for people already managing a chronic liver infection.
For these reasons, patients require regular blood tests before and during treatment. Healthcare professionals use these tests to monitor liver function, platelet levels, and other relevant indicators of safety.
Patients should promptly report concerning symptoms to their healthcare provider and follow all monitoring instructions.
The potential benefits must be weighed against these risks on an individual basis.
Will Hibsago Cure Hepatitis B Completely?
The term functional cure requires careful explanation.
A functional cure generally means that a person can maintain control of the infection without ongoing treatment, alongside the relevant laboratory findings. It does not necessarily mean that all hepatitis B virus has been eliminated from the body.
Even after treatment is discontinued, patients may need continued medical supervision because the virus can remain present and the infection may become active again.
The Hepatitis B Foundation emphasizes that a complete cure for hepatitis B remains an unmet medical goal.
People living with chronic hepatitis B should therefore continue regular appointments with their healthcare providers, including liver specialists when appropriate. Monitoring is important whether a person takes antiviral medication or has achieved treatment-free viral control.
What Does This Mean for People Living With Hepatitis B?
The FDA's approval of Hibsago represents a meaningful development in chronic hepatitis B care.
For eligible adults, the treatment may offer an opportunity to move beyond lifelong or long-term antiviral medication. The clinical findings provide evidence that some patients can maintain control of the infection after completing treatment.
At the same time, eligibility restrictions, safety concerns, and the possibility of treatment failure mean that Hibsago is not a universal solution.
Patients should discuss the potential benefits, risks, monitoring requirements, and suitability of the treatment with a qualified healthcare professional.
As research continues, Hibsago may help expand the available options for managing chronic hepatitis B and bring the medical community closer to its long-standing goal of achieving sustained control of the infection without continuous medication.
For now, informed decision-making and regular medical follow-up remain essential parts of hepatitis B care.
Sources
- U.S. Food and Drug Administration (FDA). Hibsago approval information, October 20, 2026.
- GSK. Company announcement regarding the FDA approval of bepirovirsen, October 20, 2026.
- Hepatitis B Foundation. Information on chronic hepatitis B treatment, antiviral therapy, and ongoing medical monitoring.
Medical Disclaimer
This article is intended for general informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Medical research findings and statistical data describe results observed in particular study populations and may not predict outcomes for individual patients. Hibsago may not be appropriate for everyone, and its use requires professional medical supervision. Do not stop, start, or change any medication without consulting a qualified healthcare professional. Patients with chronic hepatitis B should follow their clinician's recommendations for treatment and ongoing monitoring.